Book an Appointment

Medical News Today

  • Asthma treatment with omalizumab (xolair®), new data shows benefits

    New data analyses presented at the European Respiratory Society (ERS) Annual Congress in Vienna show that long-term treatment with omalizumab (Xolair®) significantly improves a range of outcomes for people with severe persistent allergicasthma, a chronic condition affecting an estimated 14,315 people in the UK4. Asthma can be a devastating condition, causing an average of three deaths in the UK every day, 90% of which are preventable with optimal management5.

    Read More

FirstPrevious | Pages 1 [2] of 2